Lv5
1320 积分 2024-03-29 加入
Upcoming FDA approval decisions in Q4 2026
2个月前
已关闭
When Patients Refuse Radical Cystectomy: Integrating Trimodality Therapy in the Perioperative ICI/ADC Era
6个月前
已关闭
Re-Evaluating Antibody–Drug Conjugate Linker Stability: Assessment, Interpretation, and Clinical Translation
6个月前
已完结
Pragmatic Clinical End points for High-risk NMIBC: A Path to Accelerated Market Access in Europe
6个月前
已完结
Real-world treatment sequences and overall survival in metastatic bladder cancer: The STATES-Bladder study
7个月前
已完结
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
9个月前
已完结
Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer
9个月前
已完结
HER2 and urothelial carcinoma: current understanding and future directions
1年前
已完结
Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer
1年前
已完结
Muscle-Invasive Bladder Cancer: A Watershed Moment
1年前
已完结